WO2000023623A9 - POLYMORPHISM IN Fas PROMOTER AND Fas LIGAND PROMOTER - Google Patents
POLYMORPHISM IN Fas PROMOTER AND Fas LIGAND PROMOTERInfo
- Publication number
- WO2000023623A9 WO2000023623A9 PCT/US1999/024148 US9924148W WO0023623A9 WO 2000023623 A9 WO2000023623 A9 WO 2000023623A9 US 9924148 W US9924148 W US 9924148W WO 0023623 A9 WO0023623 A9 WO 0023623A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- promoter
- fas
- individual
- polymoφh
- susceptibility
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Abstract
The use of a single nucleotide polymorph in a Fas ligand or Fas promoter region to diagnose disease is disclosed. The correlation of single nucleotide polymorphs in either a Fas ligand or Fas promoter region is correlated to individual susceptibility to autoimmune diseases or non-lymphatic cancer.
Claims
56
Claims A diagnostic method for determining autoimmune disease or cancer susceptibility comprising the step of: haplotyping an individual in a Fas ligand promoter region.
2. The method of claim 1 wherein haplotyping occurs at a polymoφh in the Fas ligand promoter region.
3. The method of claim 2 wherein said polymoφh is active in binding NF-IL6 transcription factor.
4. The method of claim 2 wherein said polymoφh is active in binding TCF/LEF-1.
5. The method of claim 2 wherein haplotyping comprises the polymoφh selected from a group consisting of: -844, -756, -478 and -205.
6. A method for identifying susceptibility to a disease, said method comprising: identifying a first Fas ligand promoter genotype at a nucleotide site of an individual; quantifying susceptibility of said individual to the disease; and comparing susceptibility of said individual to the disease to susceptibility of a second individual, said second individual having a second 57
Fas ligand promoter genotype, the second Fas ligand promoter genotype being dissimilar from the first Fas ligand promoter genotype.
7. The method of claim 1 wherein said nucleotide site is -844.
8. The method of claim 1 wherein said nucleotide site is -756.
9. The method of claim 1 wherein said nucleotide site is -478.
10. The method of claim 1 wherein said nucleotide site is -205.
11. The method of claim 1 wherein said nucleotide site binds NF- IL6 transcription factor.
12. The method of claim 1 wherein said nucleotide site binds TCF/LEF-1.
13. A Fas ligand promoter single nucleotide polymoφh.
14. The Fas ligand promoter of claim 13 wherein said single nucleotide polymoφh is -844 C/T.
15. The Fas ligand promoter of claim 13 wherein said single nucleotide polymoφh is -756 A G. 58
16. The Fas ligand promoter of claim 13 wherein said single nucleotide polymoφh is -478 C/T.
17. The Fas ligand promoter of claim 13 wherein said single nucleotide polymoφh is -205 C/6.
18. A diagnostic Fas ligand promoter primer comprising a nucleotide sequence selected from a group consisting of SEQ ID numbers 1, 2, 3, 4, 5 and 6.
19. A test kit for disease susceptibility comprising: reagents for assaying for a single nucleotide polymoφh within a Fas ligand promoter gene of an individual together with instructions for the use thereof as a diagnostic.
20. Use of a single nucleotide polymoφh within a Fas ligand promoter gene of an individual for determining susceptibility of said individual to a disease.
21. The use of claim 19 wherein said disease is selected from a group consisting of autoimmune disease and non-lymphatic cancer.
22. The single nucleotide polymoφhism according to claim 13 as described herein in any of the examples. 59
23. The method according to claim 1 as described herein in any of the examples.
24. A diagnostic method for determining autoimmune disease or cancer susceptibility comprising the step of: haplotyping an individual in a Fas promoter region.
25. The method of claim 1 wherein haplotyping occurs at a polymoφhism in the Fas promoter region.
26. The method of claim 1 wherein haplotyping comprises the polymoφh selected from a group consisting of: -690 and -95.
27. A Fas promoter single nucleotide polymoφ located at a nucleotide site greater than -660 or less than -680.
28. The Fas promoter of claim 27 wherein said single nucleotide polymoφhism is -690 T/C.
29. The Fas promoter of claim 27 wherein said single nucleotide polymoφhism is -95 G/A. 60
30. A test kit for disease susceptibility comprising: reagents for assaying for a single nucleotide polymoφh within a Fas promoter gene of an individual together with instructions for the use thereof as a diagnostic.
31. Use of a single nucleotide polymoφh within a Fas promoter gene of an individual for determining susceptibility of said individual to a disease.
32. A method for identifying susceptibility to a disease, said method comprising: identifying a first Fas promoter genotype in a nucleotide site of an individual; quantifying susceptibility of said individual to the disease; and comparing susceptibility of said individual to the disease to susceptibility of a second individual, said second individual having a second Fas promoter genotype, the second Fas promoter genotype being dissimilar from the first Fas promoter genotype.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10464498P | 1998-10-16 | 1998-10-16 | |
| US60/104,644 | 1998-10-16 | ||
| US13965999P | 1999-06-17 | 1999-06-17 | |
| US60/139,659 | 1999-06-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2000023623A1 WO2000023623A1 (en) | 2000-04-27 |
| WO2000023623A9 true WO2000023623A9 (en) | 2000-09-21 |
Family
ID=26801782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1999/024148 WO2000023623A1 (en) | 1998-10-16 | 1999-10-15 | POLYMORPHISM IN Fas PROMOTER AND Fas LIGAND PROMOTER |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2000023623A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7107155B2 (en) * | 2001-12-03 | 2006-09-12 | Dnaprint Genomics, Inc. | Methods for the identification of genetic features for complex genetics classifiers |
-
1999
- 1999-10-15 WO PCT/US1999/024148 patent/WO2000023623A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000023623A1 (en) | 2000-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008546403A5 (en) | ||
| Kariyazono et al. | Rapid detection of the 22q11. 2 deletion with quantitative real-time PCR | |
| EP1082459A1 (en) | A novel method of diagnosing, monitoring, and staging lung cancer | |
| CA2231349A1 (en) | Amplifications of chromosomal region 20q13 as a prognostic indicator in breast cancer | |
| US20090325160A1 (en) | Compositions and methods for prognosis and therapy of liver cancer | |
| EP1080227B1 (en) | Method of diagnosing, monitoring, and staging colon cancer | |
| US9512491B2 (en) | Detection of digestive organ cancer, gastric cancer, colorectal cancer, pancreatic cancer, and biliary tract cancer by gene expression profiling | |
| WO2004069189A2 (en) | Methods of assessment of drug metabolizing enzymes | |
| JP2007527241A5 (en) | ||
| CA2263895A1 (en) | Therapeutic and diagnostic applications of perlecan domain i splice variants | |
| JP2007006711A5 (en) | ||
| WO2003020118A3 (en) | Diagnosis and treatment of vascular disease | |
| Schubert et al. | BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer | |
| WO2000023623A9 (en) | POLYMORPHISM IN Fas PROMOTER AND Fas LIGAND PROMOTER | |
| WO2003026488A3 (en) | Diagnosis and treatment of vascular disease | |
| EP3645735B1 (en) | Methods and compositions for predicting chronic lung allograft dysfunction | |
| WO1999060162A1 (en) | A novel method of diagnosing, monitoring, and staging prostate cancer | |
| US7217515B2 (en) | HURP gene as a molecular marker for bladder cancer | |
| WO2005079173B1 (en) | A plynucleotide associated with a colon cancer comprising single nucleotide polymorphism, microarray and diagnostic kit comprising the same and method for diagnosing a colon cancer using the polynucleotide | |
| WO2006097462A2 (en) | Compositions and methods for treating inflammatory cns disorders | |
| US20040191785A1 (en) | Methods for diagnosing individuals with an increased risk to develop a deficiency based on mdr1 gene polymorphism | |
| JP2007166962A (en) | Method for predicting or diagnosing alzheimer's disease | |
| US7588902B2 (en) | Methods and compositions for diagnosing hepatocellular carcinoma | |
| US6861215B1 (en) | Method of diagnosing, monitoring, and staging prostate cancer | |
| US20050208499A1 (en) | Markers for diagnosing and treating breast and ovarian cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: C2 Designated state(s): CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| COP | Corrected version of pamphlet |
Free format text: PAGE 1, DESCRIPTION, REPLACED BY A NEW PAGE 1; PAGES 1/21-21/21, DRAWINGS, REPLACED BY NEW PAGES 1/21-21/21; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 09807501 Country of ref document: US |
|
| 122 | Ep: pct app. not ent. europ. phase |